American Journal of Cardiology
Volume 96, Issue 11 , Pages 1469-1475 , 1 December 2005

Does Diabetes Mellitus Abolish the Beneficial Effect of Primary Coronary Angioplasty on Long-term Risk of Reinfarction After Acute ST-Segment Elevation Myocardial Infarction Compared With Fibrinolysis? (A DANAMI-2 Substudy)

  • Mette M. Madsen, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • Corresponding Author InformationCorresponding author: Tel: 45-89-496-234; fax: 45-89-496-009.
    • ,
  • Martin Busk, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • ,
  • Hanne M. Søndergaard, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • ,
  • Morten Bøttcher, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • ,
  • Leif S. Mortensen, MSc

      Affiliations

    • UNI-C, Danish Information Technology Center for Education and Research, Aarhus, Denmark.
    • ,
  • Henning R. Andersen, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • ,
  • Torsten T. Nielsen, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • ,
  • DANAMI-2 Investigators

Received 6 May 2005 ,Revised 7 July 2005 ,Accepted 7 July 2005.

References 

  1. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association, the National Heart, Lung, and Blood Institute, the Juvenile Diabetes Foundation International, the National Institute of Diabetes and Digestive and Kidney Diseases, and the American Heart Association . Circulation . 1999;100:1132–1133
  2. Vaccarino V , Parsons L , Every NR , Barron HV , Krumholz HM . Impact of history of diabetes mellitus on hospital mortality in men and women with first acute myocardial infarction. The National Registry of Myocardial Infarction 2 Participants. . Am J Cardiol . 2000;85:1486–1489
  3. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries . J Am Coll Cardiol . 1997;30:171–179
  4. Mukamal KJ, Nesto RW, Cohen MC, Muller JE, Maclure M, Sherwood JB, et al. Impact of diabetes on long-term survival after acute myocardial infarction (comparability of risk with prior myocardial infarction) . Diabetes Care . 2001;24:1422–1427
  5. Keeley EC , Boura JA , Grines CL . Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction (a quantitative review of 23 randomised trials) . Lancet . 2003;361:13–20
  6. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al  A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction . N Engl J Med . 2003;349:733–742
  7. Grines C , Patel A , Zijlstra F , Weaver WD , Granger C , Simes RJ . Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction (six-month follow up and analysis of individual patient data from randomized trials) . Am Heart J . 2003;145:47–57
  8. Hasdai D, Granger CB, Srivatsa SS, Criger DA, Ellis SG, Califf RM, et al. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes . J Am Coll Cardiol . 2000;35:1502–1512
  9. Andersen HR, Nielsen TT, Vesterlund T, Grande P, Abildgaard U, Thayssen P, et al. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction (rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2)) . Am Heart J . 2003;146:234–241
  10. Dachman AH . New contraindication to intravascular iodinated contrast material . Radiology . 1995;197:545
  11. Nawaz S , Cleveland T , Gaines PA , Chan P . Clinical risk associated with contrast angiography in metformin treated patients (a clinical review) . Clin Radiol . 1998;53:342–344
  12. Report of the expert committee on the diagnosis and classification of diabetes mellitus . Diabetes Care . 1997;20:1183–1197
  13. Gibson CM, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM, et al. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction . J Am Coll Cardiol . 2004;44:980–987
  14. De Luca G , Suryapranata H , Ottervanger JP , Antman EM . Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction (every minute of delay counts) . Circulation . 2004;109:1223–1225
  15. Biondi-Zoccai GG , Abbate A , Liuzzo G , Biasucci LM . Atherothrombosis, inflammation, and diabetes . J Am Coll Cardiol . 2003;41:1071–1077
  16. Ross R . Atherosclerosis is an inflammatory disease . Am Heart J . 1999;138(suppl):S419–S420
  17. Rozenman Y, Sapoznikov D, Mosseri M, Gilon D, Lotan C, Nassar H, et al. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation . J Am Coll Cardiol . 1997;30:1420–1425
  18. Karha J , Bhatt DL . Percutaneous coronary intervention in diabetics . Rev Endocr Metab Disord . 2004;5:277–285
  19. Park SH , Marso SP , Zhou Z , Foroudi F , Topol EJ , Lincoff AM . Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus . Circulation . 2001;104:815–819
  20. Meier JJ , Gallwitz B , Schmidt WE , Mugge A , Nauck MA . Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? . Heart . 2004;90:9–12
  21. Schwartz TB , Meinert CL . The UGDP controversy (thirty-four years of contentious ambiguity laid to rest) . Perspect Biol Med . 2004;47:564–574
  22. Meinert CL , Knatterud GL , Prout TE , Klimt CR . A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results . Diabetes . 1970;19:789–830
  23. Garratt KN , Brady PA , Hassinger NL , Grill DE , Terzic A , Holmes DR . Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction . J Am Coll Cardiol . 1999;33:119–124
  24. Klamann A , Sarfert P , Launhardt V , Schulte G , Schmiegel WH , Nauck MA . Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide) . Eur Heart J . 2000;21:220–229
  25. Kao J, Tobis J, McClelland RL, Heaton MR, Davis BR, Holmes DR, et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention . Am J Cardiol . 2004;93:1347–1350
  26. Mayer EL , Jacobsen DW , Robinson K . Homocysteine and coronary atherosclerosis . J Am Coll Cardiol . 1996;27:517–527

 The DANAMI-2 trial was supported by grants from the Danish Heart Foundation, the Danish Medical Research Council, AstraZeneca, Bristol-Myers Squibb, Cordis, Pfizer, Pharmacia-Upjohn, Boehringer Ingelheim, and Guerbet, Denmark.

PII: S0002-9149(05)01430-X

doi: 10.1016/j.amjcard.2005.07.053

American Journal of Cardiology
Volume 96, Issue 11 , Pages 1469-1475 , 1 December 2005

Article Tools

* Image Usage & Resolution